Delphi Genetics Grants Licence to Sanofi Pasteur (SASY.PA) for Antibiotic-Free Manufacturing of Biological Products  
6/15/2009 9:08:12 AM

CHARLEROI, Belgium--(BUSINESS WIRE)--Delphi Genetics SA (“Delphi”) today announced that the company has entered into an agreement with Sanofi Pasteur, the vaccines division of Sanofi-Aventis Group, for the manufacture of biological pharmaceuticals using Delphi’s patented StabyExpressTM technology.